James Robinson is a Director of Pharmacology in the Mechanistic and Structural Biology group at AstraZeneca. His group uses a broad range of plate-based biochemical and cellular assays to deliver high quality profiling data and deep mechanistic understanding that drives lead identification and lead optimisation for a variety of early drug discovery projects. This work has supported candidate drug nominations for target classes including kinases, small GTPases and methyltransferases. Prior to joining AstraZeneca, James spent 8 years in academia working on G protein-coupled receptors. He studied for his PhD at University College London, investigating mechanisms of GPCR signalling and regulation, before undertaking a postdoc at The Scripps Research Institute, focussed on mechanistic pharmacology of the Orexin-1 Receptor.